High-content screening, typically defined as automated fluorescence microscopy combined with image analysis, is now well established as a means to study test compound effects in cellular disease-modeling systems. In this work, the authors establish several high-content screening assays in the 384-well format to measure the activation of the CC-type chemokine receptors 2B and 3 (CCR2B, CCR3). As a cellular model system, the authors use Chinese hamster ovary cells, stably transfected with 1 of the respective receptors. They characterize receptor stimulation by human monocyte chemoattractant protein-1 for CCR2B and by human eotaxin-1 for CCR3: Receptor internalization and receptor-induced phosphorylation of ERK1/2 (pERK) were quantified using fluorescence imaging and image analysis. The 4 assay formats were robust, displayed little day-to-day variability, and delivered good Z′ statistics for both CCRs. For each of the 2 receptors, the authors evaluated the potency of inhibitory compounds in the internalization format and the pERK assay and compared the results with those from other assays (ligand displacement binding, Ca 2+ mobilization, guanosine triphosphate exchange, chemotaxis). Both physiological agonists and test compounds differed significantly with respect to potencies and efficacies in the various profiling assays. The diverse assay formats delivered partially overlapping and partially complementary information, enabling the authors to reduce the probability of test compound-related technology artifacts and to specify the mode of action for individual test compounds. Transfer of the high-content screening format to a fully automated medium-throughput screening platform for CCR3 enabled the profiling of large compound numbers with respect to G protein signaling and possible tolerance-inducing liabilities. (Journal of Biomolecular Screening 2008:40-53) 
INTRODUCTION
S INCE THE DISCOVERY OF THE 1ST CHEMOKINE (now called CXC chemokine ligand 8, formerly known as interleukin-8) 19 years ago, more than 40 further receptor-promiscuous chemokines and approximately 20 different ligand-promiscuous chemokine receptors have been described. 1 Monocyte chemoattractant protein 1 (MCP-1) is a member of the chemokine family of cytokines that mediate leukocyte chemotaxis. The potent and specific activation of monocytes by MCP-1 may mediate the monocytic infiltration of tissues in atherosclerosis and other inflammatory diseases. CCR2, the only known MCP-1 receptor, exists in 2 C-terminal splicing variants, CCR2A and CCR2B. 2 Based on these differences in the cytoplasmic domain, CCR2B, the predominant splicing variant in monocytes, is mostly expressed at the cell surface, whereas a large fraction of CCR2A is maintained intracellularly. 3 Apart from monocytes, CCR2 is likewise detectable on T cells, B cells, and basophils. 4, 5 CCR3 is an eosinophil chemoattractant receptor 6 for various inflammatory CC-type chemokines such as eotaxin-1/2/3, RANTES (regulated on activation, normal T-cell expressed and secreted), MCP-3/4, and macrophage inflammatory protein-5. The expression of CCR3 on eosinophils, basophils, mast cells, and a subset of Th2 lymphocytes is in agreement with its principal role in allergic inflammation such as asthma. In this work, we characterize various physiological chemokines as well as test compounds for their agonistic or antagonistic activities against CCR2B or CCR3 in a panel of profiling assays.
The interaction between G protein-coupled receptors (GPCRs) and their extracellular ligands has proven to be an attractive point of interference for therapeutic agents. For that reason, the pharmaceutical industry has developed biochemical drug discovery assays to investigate these ligand-GPCR interactions, such as scintillation proximity assays (SPAs) 7 or the less frequently employed fluorescence polarization assays 8, 9 and fluorescence intensity distribution analysis assays. 10, 11 All the above-mentioned biochemical binding assays rely on the competition of the test compound with a labeled reference ligand. An obvious disadvantage of these binding assays is the risk of missing noncompetitive, allosteric ligands. Furthermore, the binding assay does not elucidate functional aspects of test compound activity such as full/partial agonism, neutral antagonism, inverse agonism, or positive modulation. To expand compound testing toward measuring GPCR activity, there is a need for functional medium-to-high throughput assays.
Interaction of an activated GPCR with a heterotrimeric G protein catalyzes the exchange of guanosine triphosphate (GTP) for guanosine diphosphate (GDP), enabling both Gα-GTP and βγ dimers to interact with a variety of downstream effectors. 12 The respective nucleotide exchange process on the Gα subunit can be monitored by measuring the binding of [ 35 S]GTP γ S 13 (e.g., in an SPA-based format).
Signaling downstream of the Gα subunit is dependent on the Gα isoform in use: Gα q stimulates phospholipase C (PLC); Gα i and Gα s modulate adenylate cyclase (AC) activity. If the GPCR of interest signals via PLC, the most broadly applied cell-based technique to measure GPCR activation is the Ca 2+ release assay, measured either in a fluorescent format using Ca 2+ -sensitive fluorophores 14 or in a luminescent format using aequorin and a chemiluminescent substrate. 15 Alternatively, if the GPCR of interest signals via AC, the cytosolic cyclic adenosine monophosphate (cAMP) content may be determined using various detection technologies. 16 A 3rd marker, which more recently has been applied in drug discovery to monitor the activation of G protein signaling, is the phosphorylation status of ERK1/2. 17 Apart from the use of a phospho-ERK-specific antibody in high-content screening (HCS) as applied in this work, other assay formats are available (e.g., the so-called SureFire™ assay; TGR BioSciences Pty Ltd, Thebarton, Australia).
Apart from the above assays measuring cellular signaling via G proteins, the functional activation of GPCRs may be monitored by agonist-induced receptor internalization. [18] [19] [20] The broad applicability of GPCR internalization assays is based on the common phenomenon of GPCR desensitization and has been demonstrated for numerous GPCRs. [21] [22] [23] In contrast to Ca 2+ release and cAMP assays, the internalization assay is independent of the individual GPCR intracellular signaling route. Thus, desensitization occurs independently of the associated G protein subclass or of the class of GPCR ligand. Furthermore, the imaging-based GPCR internalization assays offer the general advantages of the HCS format as described below.
In recent years, a novel technique generally referred to as highcontent screening has been introduced to the early pharmaceutical drug discovery process. 24, 25 HCS combines high-resolution fluorescence microscopy with automated image analysis. [26] [27] [28] [29] [30] [31] HCS provides several advantages over normal high-throughput screening (HTS). Cellular HTS conventionally monitors the mean response of the whole-cell population of a microtiter plate (MTP) well. In contrast, HCS can distinguish the individual response of many cells in an MTP well, which may differ with respect to the differentiation, the stage of the cell cycle, the state of transfection, or natural variability.
As a result, heterogeneous pharmaceutical drug effects on mixed-cell populations may be analyzed in a single MTP well. On-target drug effects may be cross-correlated with other phenomena such as cellular toxicity. 31 Compound artifacts such as cell lysis or compound autofluorescence may be detected. HCS permits work with endogenous targets and/or primary cells using specific antibodies or morphological image analysis. In this way, novel assay formats can be enabled that do not depend on an overall change of fluorescence or luminescence intensity from the whole MTP well.
In this article, we establish receptor internalization and ERK signaling assays for CCR2B and CCR3 in the HCS format. Potencies and efficacies of physiological agonists and test compounds in the HCS assays are compared with the results from other assay formats (ligand displacement binding, Ca 2+ mobilization, GTP exchange, chemotaxis). 
MATERIALS AND METHODS

Materials
Manual CCR2B antibody co-internalization assay
The CCR2B-expressing CHO cells were plated into BD 384 well assay plates (APs) using a Multidrop 384 dispenser (Thermo Electron, Waltham, MA) with a cell density of 2000 cells/well in Ham's F12 medium supplemented with 10% fetal calf serum, 0.4 mg/ml G418, and 1 mM sodium pyruvate. The APs were incubated in a humidified Cytomat 2 C15 incubator (Heraeus, Hanau, Germany) at 37 °C/5% CO 2 . After about 24 h, the APs were removed from the incubator and washed 3 times using a Bio-Tek ELx405 HT™ microplate washer (Bio-Tek Instruments, Winooski, VT) with 80 μl wash buffer (1× HBSS, 10 mM HEPES, pH 7.2) per well and cycle, leaving 20 μl/well after each wash cycle. Subsequently, 10 μl/well of anti-CCR2B-APC antibody in assay buffer (1× HBSS, 0.1% BSA, 10 mM HEPES, pH 7.2) was manually added to the cells using an 8-channel pipette, followed by an incubation for 60 min at 37 °C/5% CO 2 .
In the antagonistic approach, test compounds in 100% DSMO were diluted by a factor of 1:80 in dilution buffer (1× HBSS, 10 mM HEPES, pH 7.2) into a compound buffer dilution plate (CBDP) using the Cybi-Well™ 384 simultaneous pipettor (CyBio AG, Jena, Germany). Ten microliters from the CBDP were transferred to the AP, followed 2 min later by the addition of 10 μl of 250 nM hMCP-1 using the Cybi-Well™ 384 simultaneous pipettor for both steps, resulting in final concentrations of 50 nM hMCP-1 and between 25 μM and 0.79 nM for the test compounds in assay buffer plus 0.25% DMSO. In the agonistic approach, 10 μl of assay buffer plus 1.25% DMSO was added instead of the test compound solution, and 10 μl of the indicated concentrations of hMCP-1 in assay buffer were added in a 2nd step.
For both antagonistic and agonistic approaches, wells with assay buffer plus 0.25% DMSO served as vehicle control and wells receiving 50 nM hMCP-1 and assay buffer plus 0.25% DMSO served as stimulated control. The AP was then incubated for 60 min at 37 °C/5% CO 2 in a humidified incubator. The cells in the AP were fixed, and nuclei were stained by the addition of 50 μl fixation/nuclear staining solution (4% formaldehyde, 2 μM Hoechst 33342 in 1× HBSS, 20 mM HEPES, pH 7.2) using a Multidrop 384 dispenser. After an incubation at room temperature (RT) for 30 min, the AP was washed 3 times with 40 μl wash buffer per well and cycle, leaving 20 μl/well after each wash cycle, omitting the final aspiration to give a rest volume of 60 μl per well.
Manual CCR3 internalization assay based on immunofluorescence staining
The manual CCR3 internalization assay was performed similarly to the manual CCR2B internalization assay, with few modifications, explained below.
After the 1st washing step leaving 20 μl/well per well, 10 μl/well assay buffer (1× HBSS, 0.1% BSA, 10 mM HEPES, pH 7.2) was added to the cells (3000 cells/well) using a Multidrop 384 dispenser. In the antagonistic assay approach, 10 μl of compounds diluted in assay buffer in the CBDP were transferred to the AP, followed 2 min later by the addition of 10 μl of 250 nM human eotaxin-1 (hEot-1). In the agonistic approach, assay buffer plus 2.5% DMSO was added first, and the indicated concentrations of agonists were added in a 2nd step. Wells with assay buffer plus 0.5% DMSO served as vehicle control; wells containing 50 nM hEot-1 and assay buffer plus 0.5% DMSO were used as stimulated control. The AP was then incubated for 30 min at 37°C/5% CO 2 . The cells in the AP were fixed and nuclei stained by the addition of 50 μl fixation/nuclear staining solution followed by an incubation at RT for 30 min. After the washing step, the plates were subjected to immunofluorescence staining. The cells were permeabilized, and unspecific binding sites were blocked by the addition of 20 μl permeabilization/blocking solution (2% BSA, 0.1% saponin in PBS) to the AP using a Multidrop 384 dispenser, followed by an incubation for 30 min at RT. The AP was again washed 3 times with 80 μl wash buffer per well and cycle, leaving 20 μl/well after each wash cycle. Twenty microliters of primary antibody solution (anti-CCR3-APC antibody in PBS) was added to the cells using an 8-channel pipette, and the AP was subsequently incubated for 60 min at 37 °C/5 % CO 2 . The AP was washed 3 times with 40 μl wash buffer per well and cycle, leaving 20 μl/well after each wash cycle, omitting the final aspiration to give a rest volume of 60 μl per well.
Manual pERK assay for CCR2B or CCR3
The procedure for the assay for pERK in CCR2B-or CCR3expressing CHO cells was similar to the CCR3 internalization assay, with the following modifications: After an overnight incubation in the APs, the cells were starved for 6 h by removal of the complete growth medium and incubation in serum-free medium. Subsequently, the APs were washed 3 times with 80 μl wash buffer per well and cycle, leaving 20 μl/well after each wash cycle. Ten microliters per well of assay buffer was manually added to the cells using an 8-channel pipette. Upon the addition of test compound and agonist, the fixation/nuclear staining solution was added at a 5-min time point. After an incubation at RT for 30 min, the AP was washed 3 times with 80 μl wash buffer per well and cycle, leaving 20 μl/well after each wash cycle. Subsequently, the plates were subjected to 2step immunofluorescence staining as described for the manual CCR3 internalization assay using a primary anti-pERK1/2 antibody and a secondary antirabbit AF488 antibody.
Automated CCR3 internalization assay
For the automated CCR3 internalization assay, bar-coded BD 384-well APs were used. The assay was essentially performed as described for the manual CCR3 internalization assay in the agonistic approach, with the following modifications.
Prior to a run on the HCS automation platform, a cross-plate dilution series was prepared from compound source plates (CSPs; test compounds at 1 mM in 100% DMSO), as described previously. 31 Briefly, sequential dilution (each dilution step of 1:3.16 in 100% DMSO) into 5 compound DMSO dilution plates (CDDPs) was carried out using a Cybi-Well™ 384 simultaneous pipettor (CyBio AG). This scheme resulted in 5 CDDPs at compound concentrations of 316 μM, 100 μM, 31.6 μM, 10 μM, and 3.16 μM in 100% DMSO. The CSPs and the 5 CDDPs were positioned into the TeStack of the Freedom Evo 150 of an integrated robotic system; the APs were positioned in the humidified incubator (Cytomat 2 C15; Hereaus) on the platform. Plate and lid handling was performed by the CRS F3 robot (Thermo Fisher Scientific) or the RoMa within the Freedom Evo 150 (Tecan AG, Männedorf, Switzerland).
After the 1st washing step by the Bio-Tek ELx405 HT™ microplate washer and addition of assay buffer by a Multidrop 384 dispenser, the AP was transferred to the Freedom Evo 150. The test compounds in 100% DMSO from the CSPs and the 5 CDDPs were each diluted by a factor of 1:40 in assay buffer into 6 corresponding CBDPs by a TeMO 384 pipetting head (Tecan AG). Assay buffer plus 2.5% DMSO were added to columns 23 and 24/A-H of the CBDP as vehicle control, and 1 μM hEot-1 in assay buffer plus 2.5% DMSO was added to columns 23 and 24/I-P of the CBDP as stimulated control using a LiHa-8 pipettor (Tecan AG). Using the TeMO 384 pipetting head, 10 μl from each CBDP were transferred to the AP in a final 1:5 dilution step, resulting in test compound concentrations of 5 μM to 15.8 nM in assay buffer plus 0.5% DMSO.
The AP was shuttled back to the Cytomat 2 C15 incubator by the CRS F3 robot and was incubated for 30 min at 37 °C/5% CO 2 . The cells in the AP were fixed, and the nuclei were stained by the addition of 50 μl fixation/nuclear staining solution using a 2nd Multidrop 384 dispenser. After an incubation at RT for 30 min followed by a washing step, the lid of the AP was discarded, and all subsequent steps were performed without a lid. The cells were permeabilized, and unspecific binding sites were blocked by the addition of 20 μl of permeabilization/blocking solution using a 3rd Multidrop 384 dispenser, followed by an incubation for 30 min at RT. After the subsequent washing step, the plate was again transferred to the Freedom Evo. Using the TeMO 384 pipetting head, 20 μl of antibody solution (anti-CCR3-APC antibody in PBS) was added from a custom-built cooled reagent trough on the Freedom Evo 150, and the AP was subsequently incubated for 60 min at 37°C/5% CO 2 . The final washing step removed the unbound antibody and left a rest volume of 60 μl per well.
Measurement of the assay plates in the IN Cell Analyzer 3000™ ™
For automated imaging, the CRS F3 robot shuttled the APs to the IN Cell Analyzer 3000™, a confocal HCS instrument (GE Healthcare). Imaging was performed using the 647-nm, 488-nm, and/or 364-nm laser lines for excitation and 695BP55, 535BP45, and/or 450BP65 as emission filters (as described in the individual applications). For the cellular imaging, 1 image per well was taken, visualizing approximately 200 individual cells.
Image analysis
For the internalization assay, images were analyzed using the granularity (GRN0 or GRN2) algorithm of the IN Cell Analyzer 3000™. Briefly, the algorithms identified the nuclei as pixel accumulations above a specified intensity threshold in the blue (nuclear) channel image. In a specified dilated cytoplasmic mask region around these nuclei, grains of a predefined size and intensity corresponding to the internalized receptor were identified in the red (signal) channel image. In addition, the GRN2 algorithm allowed us the introduction of an intensity threshold for the signal channel (e.g., to exclude low-expressing cells). The F-grain value was calculated as follows:
Sum of pixel brightness values in test boxes corresponding to valid grains
Sum of pixel brightness values in dilated mask region
The analysis of the data was performed by the calculation of the percentage of F-grains in cells incubated with test compound compared with the F-grains of the chemokine-stimulated cells after subtraction of F-grains in the vehicle-stimulated cells.
For the pERK assay, images were analyzed using the nuclear trafficking (TRF2) algorithm of the IN Cell Analyzer 3000™. Nuclei were identified in the blue (nuclear) channel image as described before. Briefly, the algorithm generated a nuclear sampling mask by erosion of the original full nuclear mask by several pixels. To generate a cytoplasm sampling mask, the algorithm first expanded the object mask outward and then subtracted the original nuclei from the dilated mask to obtain a ring-shaped cytoplasmic sampling area. Portions of the cytoplasmic sampling mask that do not overlap with the cytoplasm (defined by background staining of the nuclear dye)
were clipped off. Using the defined nuclear and cytoplasmic sampling masks, the algorithm analyzed the image data stored in the green (signal) channel. The change in the intensity in the cytoplasmic sampling mask (CytIntsty) provided a robust parameter for the increase in pERK upon stimulation.
EC50 determination and statistical data analysis
Using the Graph Pad Prism Software version 3.00 or company-internal HTS application, dose-response curves were fitted to the equation
where x is the concentration of the test compound and Hill indicates the Hill coefficient.
Z′ values were calculated as described previously 32 :
Mean high -Mean low SD high is the standard deviation of the high values (reference agonist-stimulated controls), mean high is the mean value of the high values, and SD low and mean low are the respective numbers for the low values (vehicle-stimulated controls).
The signal-to-noise (S/N) ratio was calculated as follows:
is the absolute value of x. The other abbreviations are explained above.
The signal-to-background (S/B) ratio was calculated as follows:
Mean low
Other assay formats
Radioactive receptor membrane binding assays CCR2B. THP-1 membranes were adjusted with 25 mM HEPES, pH 7.2; 5 mM MgCl 2 ; 0.5 mM CaCl 2 ; and 0.2% BSA assay buffer to a concentration of 5 μg/15 μl. PVT-WGA beads were adjusted with assay buffer to a concentration of 0.24 mg/30 μl. For preparation of the membrane-bead-suspension, membranes and beads were incubated for 30 min at RT under rotation with a ratio of 1:2. Test compounds were dissolved in 100% DMSO to a concentration of 10 mM and were further diluted with 100% DMSO to 1 mM. All additional compound dilutions were obtained with assay buffer, diluting to a final concentration of 1% DMSO. Compounds, membrane-bead suspension, and [125I]MCP-1 (∼25,000 cpm/10 μl) were incubated. Bound radioactivity was determined by scintillation counter after 6 h. Determination of the affinity of test compounds (dissociation constant K i ) was calculated by iterative fitting of experimental data using the easy sys program. 33 CCR3. Membranes from K562-CCR3 cells were adjusted with 25 mM HEPES, pH 4; 5 mM MgCl 2 ; 1 mM CaCl 2 ; and 0.1% BSA assay buffer to a final concentration of 2 μg/200 μl. The assay was performed in the presence of 0.4 mg PVT-WGA beads, [125I]Eotaxin-1 (∼25,000 cpm), and increasing concentrations of test compounds. Bound radioactivity was determined by scintillation counter. Determination of the affinity of test compounds (dissociation constant K i ) was calculated by iterative fitting of experimental data using the easy sys program. 33 
GTP-exchange assays
Calcium influx
Cytosolic calcium influx was measured in CCR2B CHO cells loaded with Fluo-4-AM. The measurements were carried out using the FLIPR Tetra at the excitation wave length of 470 to 490 nm. For quantification, the signal intensity was integrated for 83 s after MCP-1 addition. Antagonism by compounds of calcium influx was measured using 80% effective dose (ED80) of 10 nM MCP-1 for stimulation.
Chemotaxis assays
Chemotaxis assays were performed over 4 h using human primary monocytic cells in ChemoTx plates with polycarbonate filters (5-μm pore size) according to the manufacturer's instructions.
RESULTS
CCR2B internalization assay in comparison to other CCR2B assay formats
To follow the internalization of CCR2B, a specific antibody directed against an extracellular domain of the receptor was employed: An APC-labeled form of this antibody was added to the supernatant of CHO cells overexpressing CCR2B. After allowing for antibody binding to the cell surface-exposed receptor subpopulation, the cells were vehicle treated or stimulated with hMCP-1 (100 nM final concentration) and fixed with formaldehyde 60 min after addition of the agonist. Nuclei were stained using the Hoechst 33342 dye. Images were taken using the IN Cell Analyzer 3000™ with the 364-nm laser line for excitation of Hoechst 33342 and 647-nm laser line for excitation of APC. In the hMCP-1-treated cells (Fig. 1A) , CCR2B was accumulated in perinuclear intracellular compartments, possibly recycling endosomes. In vehicle-treated cells (Fig.  1B) , CCR2B was located mostly at the cell surface. This indicates that the constitutive rate of receptor internalization was rather low and that the antibody did not significantly induce CCR2B internalization.
The extent of CCR2B internalization was quantified using an image analysis algorithm that detects red fluorescent grains of a predefined size and intensity corresponding to the endosomal receptor in a search area around the blue fluorescent cellular nuclei. The algorithm sums up the red fluorescence intensity associated with intracellular grains in the so-called F-grain value. Mean F-grain values (n = 24) of 463.2 ± 34.7 for hMCP-1-stimulated cells and 218.1 ± 12.9 for vehicle-treated cells were calculated (Fig. 1C) . Despite the rather low S/B ratio of 2.1:1, the small standard deviations render the assay format sufficiently robust with a Z′ factor of 0.42 and an S/N ratio of 6.6:1. In an agonistic dose-response experiment for hMCP-1, an EC50 of 15.3 nM was determined (Fig. 1D) . This is in close proximity to the EC50 value of 9 nM determined for the GTPγS exchange experiment (Table 1) .
Similarly, 2 further functional readouts for a Ca 2+ -influx assay (EC50 of 3 nM for hMCP-1; Table 1 ) and the most disease-relevant chemotaxis assay (EC50 of 1 nM for hMCP-1; Table 1 ) displayed EC50 values in the low nanomolar range. In all 4 above-described functional assays, the physiological agonist hMCP-1 displayed potencies that were between a factor of ∼25 and ∼400 lower than the K i value of 0.04 nM determined in a ligand displacement binding assay. This may indicate that the signaling threshold for the 4 above-analyzed functional responses is rather high with respect to the receptor occupancy by the physiological ligand. Alternatively, the 4 above-mentioned functional assays may be less sensitive to hMCP-1 because of significantly faster readout kinetics compared with the equilibrium binding assay.
The receptor internalization assay format was also suitable for an antagonistic approach. Two CCR2 reference antagonists (Fig. 1E, F) prevented hMCP-1-induced CCR2 internalization, with IC50 values of 251 nM and 470 nM, respectively ( Table  1 ). The 4 other assays (Table 1) displayed K i /IC50 values that differed only by factors of up to ∼5 from the internalization IC50s for the 2 reference compounds.
HCS pERK assay in comparison to other CCR2B assay formats
A 2nd HCS assay was established to monitor agonistinduced pERK1/2 in the same CCR2B-expressing CHO cells. The HCS monitoring of the ERK pathway is a broadly applicable assay format because most activated GPCRs-independent of their G protein coupling-induce ERK signaling. In this work, CHO cells expressing CCR2B were stimulated with hMCP-1 (100 nM final concentration) and fixed with formaldehyde 5 min after addition of the agonist. Nuclei were stained using Hoechst 33342 dye. CCR2B-dependent ERK phosphorylation was visualized by immune staining using a specific antibody against pERK, followed by an AF488-labeled secondary antibody. Images were taken using the IN Cell Analyzer 3000™ with the 364-nm laser line for excitation of Hoechst 33342 and 488-nm laser line for excitation of AF488. Stimulation with hMCP-1 resulted in high levels of both nuclear and cytoplasmic pERK ( Fig. 2A) , whereas nonstimulated cells showed only very low levels of pERK (Fig. 2B) .
The extent of ERK phosphorylation was quantified using an image analysis algorithm that sums up the green AF488 fluorescence in a cytoplasmic ring around the blue fluorescent cellular nuclei in a value referred to as "Cyt intsty." Mean values (n = 16) of 349.4 ± 15.7 for high (hMCP-1) and 194.1 ± 10.6 for low controls (no hMCP-1) were calculated (Fig. 2C) . In an agonistic dose-response experiment for hMCP-1, an EC50 of 106 pM was determined (Fig. 2D) . This EC50 value corresponds well with the receptor occupancy as determined in the binding assay (K D of 0.04 nM). With respect to the EC50 values for the other 4 functional readouts, the HCS pERK assay was more sensitive to hMCP-1 stimulation by a factor of between ∼10 and ∼150 ( Table  1) . This indicates that the pERK pathway was already activated under conditions of lower hMCP-1 receptor occupancy in comparison to the other functional assays.
Like the above CCR2 internalization assay, the pERK assay was also adaptable to an antagonistic approach. The 2 CCR2 reference antagonists ( Fig. 2E, F) respectively ( Table 1 ). The 4 other above-described functional assays (i.e., Ca 2+ influx, GTP exchange, internalization, and chemotaxis assays) displayed IC50 values ( Table 1 ) that differed by factors of between 1.1 and 6.1 from the pERK IC50s for the 2 reference compounds. The potency rank order of the 2 antagonists was different in the various functional assays (e.g., antagonist 1 is more effective than antagonist 2 in preventing Ca 2+ influx but less effective in inhibiting ERK phosphorylation). This indicates that the 2 antagonists negatively modulate CCR2 activity by distinct modes of action. The differences between the chemotaxis assay and the other cellular assay formats may further be explained by distinct modes of CCR2 signaling in the respectively employed cell types.
CCR3 internalization assay
CHO cells stably transfected with CCR3 were employed to investigate the ligand-induced internalization of CCR3. From a series of CCR3-directed antibodies that we sampled, only 1 worked acceptably in immune fluorescence experiments. When this antibody was applied in a co-internalization format as described above for CCR2, the binding of the antibody itself promoted CCR3 internalization.
Therefore, the CCR3 internalization step was conducted in the absence of antibody, and only after formaldehyde fixation were the cells immune stained using the CCR3-directed antibody. This postfixative antibody labeling (differently from the antibody cointernalization protocol as applied above to CCR2) monitors the ligand-induced net shift of CCR3 between the plasma membrane and intracellular compartments. Advantageously, such labeling provides an impression of the overall CCR3 distribution in the cells prior to ligand stimulation. A 2nd advantage is that the antibody does not interfere with test compound binding. Adversely, however, the postfixative staining does not distinguish between CCR3 that has undergone ligand-induced internalization and CCR3 that is intracellular at the resting state of the cells. For the latter reason, the assay background for nonstimulated cells may be significantly higher with the postfixative antibody labeling than with the antibody co-internalization protocol.
CHO cells expressing CCR3 were stimulated with hEot-1 (200 nM final concentration) and fixed with formaldehyde 30 min after addition of the agonist. Nuclei were stained using Hoechst 33342 dye. hEot-1-induced CCR3 internalization was detected by immune staining using an APC-labeled anti-CCR3 antibody. Images were taken using the IN Cell Analyzer 3000™ with the 364-nm laser line for excitation of Hoechst 33342 and 647-nm laser line for excitation of APC. In the hEot-1-treated cells (Fig. 3A) , CCR3 was mostly accumulated in perinuclear intracellular compartments, possibly recycling endosomes. In vehicle-treated cells (Fig. 3B) , CCR3 was partially detected at the cell surface and partially in intracellular compartments. A high constitutive rate of CCR3 internalization may account for the intracellular receptor pool in the nontreated cells.
Similar to the above-described image analysis for CCR2, the CCR3-adapted algorithm sums up the red fluorescence intensity associated with intracellular grains in the so-called F-grain value. Mean F-grain values (n = 16) of 246.4 ± 15.2 for hEot-1-stimulated cells and 63.8 ± 9.9 for vehicle-treated cells were calculated (Fig. 3C) . With a signal-to-background ratio of 3.86:1 and a Z′ value of 0.59, the assay displayed robust assay statistics. In an agonistic dose-response experiment for hEot-1, an EC50 of 4.4 nM was determined (Fig. 3D) . Resembling the above-described CCR2 study, the EC50 values for receptor internalization and the GTP exchange assay ( Table 2 ; EC50 of 1.7 nM) are in good agreement. However, the physiological agonist hEot-1 displayed potencies for CCR3 internalization and GTP exchange assay formats that are significantly weaker than the K i value of 0.19 nM determined for hEot-1 in a ligand displacement binding assay. Similar to the above-illustrated CCR2 internalization assays, this indicates that the signaling threshold for the 2 functional responses is rather high with respect to the receptor occupancy and/or that the functional assays are less sensitive to hEot-1 because of significantly faster readout kinetics compared with an equilibrium binding assay.
hEot-1 and 3 further physiological ligands, hEot-2, hMCP-2, and hMCP-4, were compared with respect to both potencies and efficacies in the 2 functional assays. In both the CCR3 internalization and the GTP exchange assay, all 4 agonists produced potencies in the low nanomolar range ( Table 2) . EC50 values for receptor internalization were higher by a factor of between 2 and 4 than the values for the GTP exchange for all 4 agonists.
Efficacies of hEot-1 for both CCR3 internalization and CCR3-mediated GTP exchange were defined as 100%. With respect to receptor internalization, the 3 further analyzed ligands-hEot-2, hMCP-2, and hMCP-4-all produced approximately the same efficacy. In contrast, these 3 agonists varied in their efficacies with respect to GTP exchange, with hEot-2 acting as The K i values were determined by a radioactive binding assay using membranes from THP-1 cells, Ca 2+ influx and guanosine triphosphate (GTP) exchange assays were done in CCR2B-expressing Chinese hamster ovary cells, and chemotaxis assays were performed with human primary monocytic cells as described in the Materials and Methods section. a super agonist (145%), hMCP-2 as a partial agonist (47%), and hMCP-4 as a regular full agonist (95%), compared with hEot-1. This suggests that the internalization of CCR3 may be induced in an all-or-nothing type of reaction, whereas the GTP exchange is a more fine-tuned response with respect to the agonist. The CCR3 internalization assay was also suitable for an antagonistic approach. Three CCR3 reference antagonists, here referred to as antagonists 1 (Fig. 4E) , 2 (Fig. 4F) , and 3 (not shown), all prevented hEot-1-induced CCR3 internalization with IC50 values of 21 nM, 38 nM, and 5.6 nM, respectively ( Table 3) . Respective K i values of 2.8 nM, 0.9 nM, and 1 nM in a radioligand binding assay ( Table 3) indicate that all 3 compound antagonists can displace the physiological peptide ligand.
High-Content Screening Assays in Chemokine Receptor-Targeted Drug Discovery
HCS pERK assay in comparison to other CCR3 assay formats
Similar to the above CCR2 pERK assay, hEot1-induced phosphorylation of ERK1/2 was observed in the CCR3-expressing CHO cells. Five minutes after agonist addition, the cells were fixed with formaldehyde and nuclei were stained using Hoechst 33342 dye. ERK phosphorylation was visualized by immune staining using the same pERK-specific antibody as employed above, followed by an AF488-labeled secondary antibody. Images were taken using the IN Cell Analyzer 3000™ with the 364-nm laser line for excitation of Hoechst 33342 and 488-nm laser line for excitation of AF488. Stimulation with hEot-1 results in high levels of nuclear and cytoplasmic pERK (Fig. 4A) , whereas nonstimulated cells show only very low levels of pERK (Fig. 4B) . Like above for the CCR2-mediated signaling, ERK phosphorylation was measured as the AF488-green fluorescence in a cytoplasmic ring around the blue fluorescent cellular nuclei in a value referred to as "Cyt intsty." Mean values (n = 16) of 213 ± 12 for high (hEot-1) and 111 ± 6 for low controls (no hEot-1) were calculated (Fig. 4C) .
The EC50 value for the CCR3-ERK phosphorylation was greater than 100 nM and thereby out of the range of testable hEot-1 concentrations under our assay conditions (Fig. 4D) . Whereas the EC50 value of MCP-1 (100 pM; Table 1 ) for CCR2-mediated ERK phosphorylation was about 150 times lower than the EC50 of MCP-1 for CCR2 internalization (15 nM; Table 1 ), the EC50 value of hEot-1 for CCR3 internalization (4 nM; Table 2 ) is at least 25 times below the extrapolated EC50 of hEot-1-induced ERK phosphorylation. With hEot-1 displaying a K D of 0.19 nM in the ligand displacement binding assay ( Table 2) , this indicates 1) that the pERK pathway was activated by hEot-1 only under conditions of high receptor occupancy and/or 2) that a slow onrate of hEot-1 reduced its potency in the pERK assay.
Automated dose-response testing for CCR3 agonists in the internalization format
An automated MTS assay format was established to detect compounds that induce CCR3 internalization. The automated assay was essentially performed as described above for the manual CCR3 internalization assay in the agonistic mode, with the following modifications.
One day prior to the automated run, six 384-well APs were prepared with 3000 cells per well and were placed in a humidified incubator of the robotic platform. We obtained a 384-well CSP from our compound storage facility. The wells in columns 1 to 22 of this CSP contained up to 352 distinct compound solutions in 100% DMSO, each with a test compound concentration of 1 mM. A 384-tip pipetting device was employed to carry out 5 consecutive DMSO dilution cycles from the CSP, diluting the test compound solution by a factor of 3.16 in each cycle. This cross-plate dilution scheme significantly accelerates the process of compound dilution for dose-response experiments, as described previously. 31 The robotic platform carried out the completely automated assay protocol as described in the Materials and Methods section. The automated processing of eight 384well APs required 6.5 h. Imaging and automated image analysis of eight 384-well APs, either parallel or subsequential to the automated liquid handling, required approximately 8 h.
Only the compound dilution steps in pure DMSO were carried out independently of the automated run. Compound dilution into The K i values were determined by a radioactive binding assay using membranes from CCR3-expressing K562 cells, as described in the Materials and Methods section.
the assay buffer was conducted in parallel to the AP preparation during the automated run. This bears the combined advantage of minimizing and standardizing incubation times for the test compounds in aqueous solution, where precipitation and degradation are facilitated. From 387 test compounds, 28 activated CCR3 internalization in a dose-responsive way, with EC50 values less than 1 μM. In Figure 5 , the respective EC50 values from 2 independent automated runs are plotted against each other. This experiment demonstrates the robust day-to-day reproducibility (r 2 = 0.75) of the automated testing.
DISCUSSION
In this work, a variety of assay technologies for measuring ligand receptor binding, receptor activation, and receptor signaling were applied to CCR2B and CCR3. The above-described assay formats differ with respect to information content, assayability, feasibility, reliability, and throughput. In detail, the binding assay will most likely not allow the identification of allosteric inhibitors but is applicable to the identification of competitive compounds with a robust high throughput and low cost. The GTP γ S exchange assay enables the differentiation between full and partial agonists, neutral antagonists, and inverse agonists with a similarly high throughput as the binding assay and medium cost. The Ca 2+ influx assay provides a direct functional readout upon receptor stimulation at high throughput and medium cost. The chemotaxis assay is the most relevant functional readout for CCR2 inhibitors with respect to compound efficacy in vivo but does not provide additional (off-target) information and is limited (because it is based on primary cells) with respect to throughput and robustness. High-content assay formats are feasible for high throughput but are generally used as secondary assays because of the complexity and the relatively high costs. The power of HCS assays, however, lies in the potential for multiplexing downstream signaling events (e.g., ERK phosphorylation with the receptor internalization). The phosphorylation of ERK1/2 is a universal assay format with respect to GCPR signaling that can easily be transferred to any different cellular background. Moreover, HCS allows us to generate additional information by monitoring additional readouts in the same assay, such as rounding or loss of cells in case of a toxic compound effect, enhancement of plasma membrane GPCR levels by an inverse agonist, or the enhancement of pERK levels by a compound with a stressinducing side effect.
All assay formats delivered partially complementary information: A binding assay typically produces a data set that is focused on the ligand-receptor interaction itself; the cellular assay provides a view on the cellular context of the ligandinduced receptor activation. The binding assay does not reveal the functional activity of the test compounds as full/partial agonists, neutral antagonists, inverse agonists, or allosteric modulators. Binding assays enable equilibrium binding or kinetic displacement measurements so that both K D -type and k on /k off -type values may be derived. In contrast, the signal kinetics of cellular assays depend not only on the on-/off-rate of the ligand but also on the kinetics of the employed reporter system. Ligand-receptor binding equilibria are typically not established during the course of a transient cellular response, such as a Ca 2+ release from the ER or the HCS formats. Furthermore, the apparent intrinsic efficacy and potency of a ligand in a functional assay is significantly influenced by the G protein coupling, the signaling chain, and the ultimate assay readout.
Always a challenge in the area of cellular assays is the question as to whether the observed test compound effect is indeed based on the interaction of the test compound with the target receptor. Multiplexing of several signaling events and highcontent analysis help to reduce the probability of technologybased artifacts. In this context, the above-described cellular formats provide numerous options to survey various aspects of receptor activation and subsequent signaling such as the generation of 2nd messengers, protein phosphorylation, or protein translocations.
In summary, all discussed biochemical and cellular assays have their individual merits, with each approach providing advantages over the other under particular circumstances. The diversity of assay formats to characterize GPCR ligands delivers partially overlapping information, thereby cross-validating experimental answers and excluding technology-based assay artifacts. In our opinion, an appropriate assay panel for an extended pharmacological characterization of GPCR ligands should include data on binding, G protein signaling via various pathways, and GPCR internalization. For drug discovery, an approach may be employed that progressively introduces additional complexity, for example, starting with the isolated receptor target in membrane fragments and then ultimately proceeding to integrated cellular assays.
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FIG. 5.
Correlation between 2 independent automated dose-response determinations for test compounds. CCR3-expressing Chinese hamster ovary cells were incubated with test compounds at 6 different concentrations in duplicate, fixed with formaldehyde after 30 min, and subjected to immunofluorescence staining for CCR3. Dose-response curves for 2 independent experiments (measurements 1 and 2) were fitted using a company-internal high-throughput screening data analysis application. All EC50 values <1 μM from these 2 experiments were plotted against each other.
